Vertex Pharmaceuticals (NASDAQ: VRTX) might be one of those special cases. Should you buy Vertex stock hand over fist before ...

Vertex Pharmaceuticals Inc. closed 19.80% below its 52-week high of $519.88, which the company reached on November 8th.

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Vertex also has multiple other catalysts on the way in 2025 and over the next few years. It usually doesn't matter if you buy a given stock immediately or two weeks later. Sure, the stock could ...

Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...

Sometimes, a stock has a potential catalyst right around the corner. In such a case, investors could be much better off buying sooner rather than later. What's so special about Jan. 30 for Vertex?

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

ORG Partners LLC boosted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 108.2% ...

This readout is viewed as a significant potential catalyst for Vertex's stock, as success in chronic pain could substantially expand the market opportunity for the company's pain franchise.